NVSNovartis PharmaceuticalsSigning up patients
Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
Chronic Myelogenous Leukemia · Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 50 (planned)
- Started
- Apr 28, 2026
- Main results expected
- Feb 23, 2033
- Fully finished
- Feb 23, 2033
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
MMR at Week 48
Measured over: 48 weeks
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07354074 · record last updated 2026-10-15 · checked 2026-11-09 15:47 UTC